ArticlePloS one2019

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.

Matthieu Dusselier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.